Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SLC 0111

Next Previous
Drug Profile

SLC 0111

Alternative Names: SLC-0111; WBI-5111

Latest Information Update: 04 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SignalChem Lifesciences
  • Developer SignalChem Lifesciences; Welichem Biotech
  • Class Cytostatics; Small molecules
  • Mechanism of Action Carbonic anhydrase IX inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pancreatic cancer
  • No development reported Solid tumours

Most Recent Events

  • 04 Jun 2024 SLC 0111 is still in phase I trials for Pancreatic cancer (Late-stage disease, Combination therapy, Metastatic disease) in Canada (Signalchem lifesciences pipeline, May 2024)
  • 28 May 2024 No recent reports of development identified for phase-I development in Pancreatic-cancer(Combination therapy, Late-stage disease, Metastatic disease) in Canada (PO)
  • 16 May 2024 Welichem Biotech and British Columbia Cancer Agency terminates a phase Ib clinical trial in Pancreatic cancer (Metastatic disease, Combination therapy, Late-stage disease) in Canada (PO), due to the changing treatment landscape (NCT03450018)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top